p70S6K inhibitor LY2584702

Drug Overview

p70S6K inhibitor LY2584702 (also known as LY2584702) is an investigational, orally bioavailable, small-molecule p70 ribosomal protein S6 kinase (p70S6K) inhibitor. It is designed as a highly selective and potent adenosine triphosphate (ATP)-competitive antagonist of the p70S6K enzyme, which is a critical downstream effector of the PI3K/Akt/mTOR signaling pathway.

In the clinical landscape of March 2026, LY2584702 is recognized for its historical development as a potential oncology therapeutic and its more recent exploration in metabolic research. The PI3K/mTOR pathway is frequently dysregulated in human cancers, driving uncontrolled protein synthesis, cell growth, and survival. While earlier treatments targeted the “upstream” mTOR complex, LY2584702 was engineered to block the pathway further “downstream” at the p70S6K level. This specificity was intended to avoid the negative feedback loops (such as Akt activation) often triggered by direct mTOR inhibition. Developed by Eli Lilly and Company, the drug reached Phase I clinical trials for advanced solid tumors. However, due to a lack of significant clinical efficacy as a single agent and challenges with tolerability in combination therapies, its primary development in oncology has largely transitioned into academic and metabolic research, where it is being studied for its effects on dyslipidemia and obesity.

• Generic Name: p70S6K inhibitor LY2584702.
• Code Name: LY2584702.
• Drug Class: Selective p70S6K Inhibitor; PI3K/mTOR Pathway Antagonist.
• Mechanism: ATP-competitive inhibition of p70S6K, preventing phosphorylation of the S6 ribosomal protein.
• Route of Administration: Oral (Capsule/Tablet).
• FDA Approval Status: Investigational/Terminated. As of March 2026, LY2584702 is not FDA-approved. Development for oncology was largely discontinued following Phase I results, though it remains a vital tool in preclinical research and metabolic studies.

What Is It and How Does It Work? (Mechanism of Action)

LY2584702 works by “jamming” the final assembly line of protein production within a cancer cell.

1. Blocking the PI3K/mTOR Exit Point

In many tumors, the PI3K/mTOR pathway is overactive, constantly sending signals to grow. p70S6K is the “last stop” in this communication chain.

• The Normal Signal: When mTOR is activated, it phosphorylates p70S6K, which then goes on to phosphorylate the S6 ribosomal protein. This “switch” tells the cell’s ribosomes to start mass-producing proteins.
• The Inhibition: LY2584702 sits in the ATP-binding pocket of p70S6K. By blocking ATP, the drug prevents the kinase from functioning.

2. Inhibiting Ribosomal Function

By stopping p70S6K, the drug effectively prevents the phosphorylation of the S6 subunit.

• Translational Arrest: Without a phosphorylated S6 protein, the ribosome cannot properly translate the mRNAs needed for cell cycle progression and survival.
• Growth Inhibition: This leads to a decrease in global protein synthesis, forcing the tumor cell to stop dividing or enter a state of dormancy.

3. Metabolic Reprogramming (2025-2026 Focus)

Recent research in 2025 has shown that inhibiting p70S6K with LY2584702 can also “reset” lipid metabolism.

• Dyslipidemia Management: In research models, the drug has been shown to reduce plasma low-density lipoprotein (LDL) and triglycerides.
• Hepatosteatosis: It appears to mitigate diet-induced fat accumulation in the liver, making it a subject of interest for treating obesity-related metabolic disorders.

Clinical Indications and Research Status (2026)

In the current year, LY2584702 is primarily utilized as a benchmark in metabolic and translational research:

• Advanced Solid Tumors (Historical): Phase I trials (NCT00839176 and NCT00928239) evaluated the drug in patients with refractory solid tumors. While it successfully inhibited its target (pS6) in patient skin biopsies, it did not produce the expected tumor shrinkage as a single agent.
• Combination Strategies: It was evaluated in combination with erlotinib (an EGFR inhibitor) and everolimus (an mTOR inhibitor). The erlotinib combination was poorly tolerated due to gastrointestinal issues, while the everolimus combination showed only limited clinical benefit.
• Metabolic Syndrome Research: In 2024–2026, the focus shifted to the drug’s ability to “hamper fat mass expansion.” It is currently being used to study how p70S6K inhibition can modify gene expression patterns in adipose tissue and liver.
• Hepatotoxicity Studies: Scientists are investigating the metabolic byproduct of the drug (4-aminopyrazolo[3,4-d]pyrimidine), which may be responsible for the liver toxicity observed at higher doses.

Dosage and Administration Protocols

As an investigational drug, the following dosing parameters were established during its clinical oncology phase:

Clinical Efficacy and Research Results (2024–2026)

The legacy of LY2584702 in 2026 is defined by its role as a “proof-of-concept” for kinase inhibition:

• Target Engagement: Clinical data confirmed that LY2584702 is highly effective at reaching its target. At the MTD, it inhibited ribosomal protein S6 phosphorylation by more than 80% in surrogate tissues.
• Preclinical Success: In mouse xenograft models of HCT116 colon carcinoma and U87MG glioblastoma, the drug demonstrated significant antitumor efficacy at doses as low as 12.5 mg/kg.
• Metabolic Efficacy (2026 Update): Recent studies published in early 2026 indicate that oral administration of LY2584702 protects against diet-induced obesity in mice by ameliorating dyslipidemia and reducing hepatic steatosis.

Safety Profile and Side Effects

The clinical development of LY2584702 was hampered by significant gastrointestinal side effects, which limited the doses that could be safely achieved in humans.

1. Gastrointestinal (GI) Toxicity

• Nausea and Vomiting: The most frequent and dose-limiting side effect. Grade 3 nausea was common at higher dose levels.
• Management: These symptoms often required the intensive use of anti-emetics.

2. Hepatotoxicity (Liver Stress)

• Hepatitis Risk: Some patients showed elevations in liver enzymes, potentially linked to the chemical breakdown of the drug into 4-APP.
• Monitoring: Regular liver function tests (LFTs) were mandatory during all clinical trials.

3. General Systemic Effects

• Fatigue: A common report among patients in Phase I studies.
• Decreased Appetite: Often secondary to the GI disturbances.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, LY2584702 is a tool used to study “Proteome Maintenance.” Researchers are investigating how p70S6K inhibition can “slow down” the aging process of Hematopoietic Stem Cells by reducing the accumulation of misfolded proteins. In 2026, there is also focus on “Anoikis Sensitization,” where scientists use the drug to show that p70S6K inhibition can make cancer cells more sensitive to “detachment-induced” death, potentially preventing the survival of circulating tumor cells that cause metastasis.

Patient Management and Practical Recommendations

For Researchers and Clinical Trial Participants:

• Pharmacodynamic Monitoring: Measuring the levels of phosphorylated S6 (pS6) in the blood or tissue is the standard method to verify the drug is working.
• Liver Monitoring: Frequent monitoring of AST/ALT and bilirubin is required to catch early signs of liver toxicity.

“Do’s and Don’ts” List:

• DO report any “uncontrolled vomiting” or “yellowing of the eyes” (jaundice) immediately to the study team.
• DO monitor your lipid profile if taking this drug as part of a metabolic study, as it can cause rapid changes in cholesterol levels.
• DON’T consume grapefruit or grapefruit juice, as these can interfere with the liver enzymes (CYP450) that process the drug.
• DON’T ignore persistent upper-abdominal pain, which may be a sign of liver or gallbladder stress.

Legal Disclaimer

The information provided is for educational and historical purposes only and does not constitute medical advice. LY2584702 is an investigational agent and is not approved by the U.S. FDA for the treatment of cancer or metabolic disorders. Clinical development for oncology has been terminated. Always consult with a board-certified oncologist or endocrinologist regarding currently approved treatments for advanced solid tumors or dyslipidemia.